CRISPR/Cas9-Engineered 3D Tissue Culture Models of Drug-Resistant Melanoma

Elizabeth Gillies, Ph.D.
Scientist, ATCC Cell Biology





Credible Leads to Incredible™

ATCC – Credible leads to Incredible

- ATCC has provided credible biomaterials for over 90 years
- We continue to cultivate collaboration
  - Among scientists across disciplines
  - Essential for accelerating innovative research
  - Leading to incredible, high-impact results
- Our Cultivating Collaboration pledge: We bring scientists together to discuss
  - Breakthroughs in the state of science
  - Multidisciplinary approaches to key areas of research
  - Breaking the silos that impede research
- Our partnership with you, the scientific community, allows us all to reach the incredible

Outline



I. Precision genome engineering of new cell-based models for drug discovery

II. A375 drug-resistant melanoma model cell lines – ATCC quality and reproducibility

III. Melanoma model lines 2D/3D tissue culture system

Precision genome engineering of models for drug discovery

This section covers

- Precision genome engineering with CRISPR/Cas9
- Applications of CRISPR/Cas9 in drug discovery
- ATCC CRISPR/Cas9 genome editing platform
- Cell-based models of acquired drug resistance
- BRAF mutation in melanoma
- Mechanisms of acquired BRAF inhibitor resistance



Precision gene editing with CRISPR/Cas9



RNA-guided Cas9 endonuclease cuts genomic DNA at a precise genomic locus



Cellular DNA repair mechanisms repair this damage using Non-Homologous End Joining or Homology Directed Repair

With CRISPR/Cas9, it is now feasible and cost-effective to use human cells as genetically engineered

Ran F, *et al*. Nat Protoc 8(11): 2281-308, 2013.

Application of CRISPR/Cas9 in drug discovery



Functional Screening

Generate precision cell models

Generate animal models of human disease

Generate therapeutics

Genome-scale knockout, inhibition, and activation screens

Isogenic cell lines for drug target validation, mechanistic analysis, and drug screening

CRISPR/Cas9 shows promise as a therapeutic agent

ATCC

ATCC CRISPR/Cas9 gene-editing platform

Cell Biology

- ✓ Cell banking
- ✓ Cell line authentication
- ✓ Modification of extant lines
- ✓ Single cell cloning
- ✓ Phenotype validation



Molecular Biology

- ✓ CRISPR reagent design
- ✓ Expression vector toolbox
- ✓ Molecular cloning
- ✓ ddPCR™ and qPCR
- ✓ Sanger and next-gen sequencing

ATCC® CRISPR Engineering Platform



- New cell-based models of human disease

Cell-based models of acquired drug resistance



Isolation of resistant cells from clinical tumor samples

- Relatively easy to isolate
- Not time intensive
- New line is uncharacterized
- Heterogeneous mix of cells
- No control cell line



Progressive dosing of known cancer cell line

- Can take up to 18 months
- Long-term drug pressure causes spurious mutations
- Accumulation of spurious mutations makes parental line a poor control
- Heterogeneous mix of cells
- Constant drug pressure required to maintain drug-resistance phenotype



CRISPR/Cas9 genome editing

- Precise gene-editing method
- Homogeneous cell population
- Parental cell line is an excellent control
- Defined drug-resistance mechanism
- No drug pressure required during routine cell culture
- Stable resistance phenotype
- Highly reproducible results

BRAF mutation in melanoma

Ras/Raf/MEK/ERK MAP kinase signaling pathway



Cell survival and proliferation

- 50% of melanomas carry an activating BRAF mutation and are sensitive to BRAF inhibitors



Week 1 **Week 15** **Week 23**

However, BRAF inhibitor resistance can develop after several months of treatment, resulting in tumor regrowth

Reproduced from Wagle N, *et al.* J Clin Oncol 29(22): 3085-

Mechanisms of acquired BRAF inhibitor resistance

Secondary mutations bypass BRAF Inhibition



Cell survival and proliferation

- Treatment with BRAF inhibitors drives acquired BRAF inhibitor resistance

- Continued BRAF-inhibitor treatment frequently leads to secondary activating mutations in the Ras/Raf/MEK/ERK MAP kinase signaling pathway
- Secondary mutations bypass BRAF inhibition, resulting in:
  - BRAF inhibitor resistance
  - Cancer progression
  - Poor clinical outcomes
- Chemotherapeutics and treatment regimens do not address melanomas with acquired-inhibitor resistance
- Development of new drugs and combination therapies is hindered by the lack of well-controlled and physiologically relevant cell-based models

ATCC

A375 drug-resistant melanoma model cell lines – ATCC quality and reproducibility

This section covers:

- Use of CRISPR/Cas9 to create isogenic drug-resistant melanoma model cell lines
- ATCC drug-resistant isogenic melanoma model cell system
- Genome- and transcript-level validation of melanoma model lines
- Off-target cut and Cas9 integration of melanoma model lines
- Functional validation of isogenic melanoma model drug resistance



CRISPR/Cas9 used to create isogenic melanoma model cell lines



A375 human melanoma line carries the oncogenic BRAFV600E mutation

ATCC Quality and Standards

- Functionally validated
- Cell line purity and sterility confirmed
- Species identity verified
- Post-freeze viability verified
- Target site genotyped



Drug-resistant isogenic melanoma model cell system

Cell Line Name	ATCC® No.	BRAF V600E	Engineered Mutation	Engineered Genotype	BRAF Inhibitor Resistance	MEK Inhibitor Resistance	3D Functional Validation
Unedited A375	CRL-1619™	+	N/A	N/A	−	−	+
KRAS Mutant-A375 Isogenic	CRL-1619IG-1™	+	KRAS G13D	heterozygous	+	−	+
NRAS Mutant-A375 Isogenic	CRL-1619IG-2™	+	NRAS Q61K	heterozygous	+	−	+
MEK1 Mutant-A375 Isogenic	CRL-1619IG-3™	+	MEK1 Q56P	homozygous	+	+	+



Genome and transcript-level validation of melanoma model lines

Cell Line Name	Engineered Genotype	Target Site Genome Sequence	Transcript Sequence of Target Gene
KRAS Mutant-A375 Isogenic	KRAS G13D heterozygous		
NRAS Mutant-A375 Isogenic	NRAS Q61K heterozygous		
MEK1 Mutant-A375 Isogenic	MEK1 Q56P homozygous		

Isogenic lines are screened for off-target cut and Cas9 integration

MEK1 mutant A375 isogenic off-target cut screening results

Genomic Coordinates	Strand	MM	Target Sequence	PAM	Nearest Gene	Location	MEK1 Mutant A375 Isogenic
chr15:66434832-66434854	+	0	CATGTTGG[TGATAGTCATCC]	CGG	MAP2K1	target site	N/A
chr1:10853864-10853886	-	3	AATGATGG[TGACAGTCATCC]	TGG	HSPE1P24	intergenic	PASSED
chr11:108532803-108532825	-	4	CAAGTATG[AGATAGTCATCC]	AGG	EXPH5	intronic	PASSED
chr19:5663907-5663929	+	4	ACTCTTGG[TGAAAGTCATCC]	TGG	SAFB	intronic	PASSED
chr3:185058989-185059011	-	4	CTTTTTGA[TCATAGTCATCC]	TGG	VPS8	intergenic	PASSED
chr22:29816431-29816453	+	3	CAAGTTGG[AGTTAGTCATCC]	AGG	ASCC2	intronic	PASSED
chr8:137426391-137426413	-	4	GATAATGG[TGACAGTCATCC]	AGG	ZYXP1	intergenic	PASSED
chr15:29974505-29974527	-	4	CATTTTCT[TAATAGTCATCC]	CGG	TJP1	intergenic	PASSED
chr2:86435176-86435198	-	3	CATGTTTT[TGAGAGTCATCC]	AGG	KDM3A	intergenic	PASSED
chr20:4745349-4745371	-	3	AATGTTGG[TGTCAGTCATCC]	TGG	PRNT	intergenic	PASSED
chr3:112605446-112605468	+	4	CATGATGA[CGGTAGTCATCC]	TGG	CCDC80	exonic	PASSED

```
>Reference genome sequence
>Unmodified A375 OT1 HSPE1P24 - intergenic
>MEK1 Mutant A375 OT1 HSPE1P24 - intergenic
>OT1 HSPE1P24 - intergenic
                *         *         *         *         *         *         *         *         *         *
185>ACCATCACTACCATCACCAGGATGACTGTCACCATCATTATCACTGCCATCATTACCACCATAATCATCACCATCTATCACTACCACTATTGTTATCACC>284
600>ACCATCACTACCATCACCAGGATGACTGTCACCATCATTATCACTGCCATCATTACCACCATAATCATCACCATCTATCACTACCACTATTGTTATCACC>699
601>ACCATCACTACCATCACCAGGATGACTGTCACCATCATTATCACTGCCATCATTACCACCATAATCATCACCATCTATCACTACCACTATTGTTATCACC>700
  1>~~~~~~~~~~~~~~~~~~~~~GGATGACTGTCACCATCATT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>20
```



MEK1 mutant A375 isogenic line plasmid integration screening

BRAF inhibitor resistance in melanoma model lines

2D functional validation





No resistance to nonspecific chemotherapeutics in melanoma model lines

2D functional validation





MEK inhibitor resistance in the MEK1 isogenic melanoma model

2D functional validation





Combination inhibitor treatment in drug-resistant MEK1 mutant-A375 isogenic cell line

Two-target MAP kinase pathway inhibition in multidrug-resistant MEK1 melanoma model



Primary Mutation BRAF V600E

Secondary Mutation MEK1 Q56P

Normal signaling

Inhibited signaling

Benefits of Combination Drug Treatment

- Lower doses required
- Reduced side effects
- Improved clinical outcomes

½ dose BRAF inhibitor + ½ dose MEK inhibitor = synergistic pathway inhibition

ATCC

MEK1 mutant-A375 isogenic cell line is sensitive to combination MEK/BRAF inhibitors



BRAF inhibitor dose-response



Combination inhibitor dose-response



MEK inhibitor dose-response

ATCC

MAP kinase signaling in MEK1 mutant-A375 isogenic cell line



Cell Lines Tested

A375 - original A375 melanoma cell line

MEK1 - MEK1 Mutant-A375 Isogenic Line

Drug Key

Db - Dabrafenib 1uM

V - Vemurafenib 2uM

Db/T - 0.5uM each

T - Trametinib 1uM

B - Binimetinib 2uM

Dx - Doxorubicin 2uM

-- - DMSO control

ATCC

Melanoma model lines 2D/3D tissue culture system

This section covers:

- Model systems for drug screening and validation
- Drug resistant 2D/3D melanoma model cell system
- Melanoma model lines 3D spheroid formation
- Functional validation of 3D tissue culture drug-resistant model melanoma models
- Automated analysis of 3D melanoma model drug response



Model systems for drug screening and validation



2D Tissue Culture

- Human host system
- Least time intensive, lowest cost
- Simple automated assay readout
- Lowest system complexity
- Highest clinical trial failure rate



3D Tissue Culture

- Human host system
- Higher system complexity
- Potential for lower clinical trial failure rate
- Slightly increased time and cost
- More complex automated assay readout

Animal Model

- Highest system complexity
- Lowest clinical trial failure rate
- Most time intensive, highest cost
- Results can be difficult to interpret
- Non-human model system

All of our isogenic melanoma model cell lines have been functionally validated in both 2D and 3D tissue culture

ATCC

Drug-resistant isogenic 2D/3D melanoma model cell system

	Unmodified A375	KRAS Mutant-A375 Isogenic	NRAS Mutant-A375 Isogenic	MEK1 Mutant-A375 Isogenic
2D Monolayer				
3D Spheroid				

3D spheroid formation in melanoma model lines

Cell Line	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
Unmodified A375							
KRAS Mutant-A375 Isogenic							
NRAS Mutant-A375 Isogenic							
MEK1 Mutant-A375 Isogenic							

ATCC

3D functional validation of melanoma model lines



Automated analysis of 3D spheroid drug response







Nuclei count

Spheroid size + stain intensity

Raw data

Normalize to un-drugged condition

Average replicates

Final dataset

BRAF inhibitor resistance in NRAS- and KRAS-mutant A375 isogenic melanoma model lines

3D functional validation







MEK and BRAF inhibitor resistance in MEK1-mutant A375 isogenic cell line

3D functional validation





Key points

CRISPR/Cas9 engineering of cell-based models for drug discovery	▪ Applications of CRISPR/Cas9 in drug discovery ▪ ATCC CRISPR/Cas9 genome editing platform ▪ Cell-based models of acquired drug resistance ▪ Mechanisms of acquired inhibitor resistance
Precision engineered models of inhibitor-resistant melanoma	▪ Use of CRISPR/Cas9 to create isogenic drug-resistant melanoma model cell lines ▪ ATCC drug-resistant 2D/3D isogenic melanoma model cell system
Screening and functional validation of isogenic A375 melanoma models	▪ Genome and transcript level validation of melanoma model lines ▪ Off-target cut and Cas9 integration of melanoma model lines ▪ Functional validation of isogenic melanoma model drug resistance
Automated analysis of drug response in 3D A375 isogenic melanoma models	▪ Model systems for drug screening and validation ▪ Melanoma model lines 3D spheroid formation ▪ 3D tissue culture drug resistant model functional validation ▪ Automated analysis of 3D melanoma model drug response

ATCC

Conclusions: Key features of engineered melanoma models

Clinically relevant cancer cell models are critical both for studies of molecular and cellular mechanisms of tumorigenesis and for the design and screening of novel cancer therapeutics. With new genome editing tools such as CRISPR/Cas9, ATCC can now use its extensive cell-banking resources to generate novel isogenic disease model cell lines. We have engineered isogenic lines with mutations in key oncogenes that are ideally suited for the identification of novel, personalized treatment regimens.

Key Features of ATCC CRISPR/Cas9 engineered isogenic melanoma model cell lines:

- Parental line is carefully selected for disease and drug-target relevance. Parental line is well characterized.
- Precisely edited isogenic cell lines have been thoroughly validated at genomic, transcript, protein, and cellular bio-functional levels.
- Additional bio-functional characterization with specific inhibitors has been performed for isogenic melanoma model lines in both 2D and 3D tissue culture.
- When used together with authenticated parental line, CRISPR/Cas9-edited isogenic melanoma model lines provide useful *in vitro* models for both basic and translational research

ATCC

Disclaimer



Thank you for joining today!

Register for more ATCC webinars at

www.atcc.org/webinars

Learn more about isogenic cell lines at

www.atcc.org/isogenics

For more cancer research resources visit

www.atcc.org/cancer



Please email additional questions to: tech@atcc.org